Stock Details
4523.T is Eisai Co., Ltd.'s stock. Stock exchange Tokyo (Currency JPY). Average price in 50 days is 8,884.08¥. Average daily volumn in 3 months 2.69M. Market cap 2.34T



Stock symbol : 4523.T. Exchange : Tokyo. Currency : JPY
Lastest price : 8,149.00¥. Total volume : 1.21M. Market state CLOSED
Click reload if you want to check the lastest price on market!!!

Eisai Co., Ltd. (4523.T)
Last Price
8,149.00¥
Change
-132.00
Volume
1.21M

Previous Close8,281.00
Open8,288.00
Day Range8,131.00-8,288.00
Bid8,145.00 x N/A
Ask8,151.00 x N/A
Volume1.21M
Average Volume2.69M
Market Cap2.34T
Beta0.21
52 Week Range5,011.00-10,050.00
Trailing P/E72.17
Foward P/E44.26
Dividend (Yield %)1.96%
Ex-Dividend Date2023-03-30



Financial Details


According to Eisai Co., Ltd.'s financial reports the company's revenue in 2022 were 756.23B an increase( +17.21%) over the years 2021 revenue that were of 645.94B. In 2022 the company's total earnings were 47.95B while total earnings in 2021 were 42.12B( +11.9%).


Loading ...



Organization

Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted... medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.

eisai-co-ltd-logo

Market Cap:
2.34T
Revenue:
756.23B
Total Assets:
1.24T
Total Cash:
309.63B


News about "Eisai Co., Ltd."

Eisai Co. Ltd. ADR

Source from : Wall Street Journal - 5 days ago

Yoshiteru Kato Director Eisai Co., Ltd., Eisai Manufacturing Ltd. Hiroyuki Kato Director Eisai Co., Ltd. Hideki Hayashi Director Eisai Co., Ltd., Ea Pharma Co., Ltd ...See details»


Eisai : EMA Accepts MAA For Lecanemab As Treatment For Early Alzheimer's Disease

Source from : Business Insider - 2 days ago

The European Medicines Agency has accepted a marketing authorization application for lecanemab (Brand Name in the U.S.: LEQEMBI), an ...See details»


eisai-marketing-authorization-application-for-lecanemab-as-treatment-for-early-alzheimers-disease-accepted-by-european-medicines-agency-image

Eisai: Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Accepted by European Medicines Agency

Source from : Asia One - 2 days ago

TOKYO and CAMBRIDGE, Mass., Jan 27, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that the European Medicines Agency (EMA) has accepted a marketing authorization application ...See details»


Eisai Co., Ltd. (4523)

Source from : Investing - 4 days ago

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...See details»


EISAI FILES MARKETING AUTHORIZATION APPLICATION FOR ANTI-AMYLOID-BETA PROTOFIBRIL ANTIBODY LECANEMAB FOR EARLY ALZHEIMER'S DISEASE IN JAPAN

Source from : Yahoo Finance - 13 days ago

TOKYO and CAMBRIDGE, Mass., Jan. 15, 2023 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate ...See details»


Eisai says new Alzheimer's drug to cost $26,500 annually

Source from : Emirates247 - 22 days ago

Japanese drugmaker Eisai Co Ltd said on Friday it had priced its newly approved Alzheimer's disease drug called Leqembi at $26,500 a year. Eisai developed the drug with Biogen Inc. Wall Street ...See details»


health-news-roundup-eisai-files-for-approval-of-alzheimers-drug-in-japan-who-recommends-that-china-monitor-excess-covid-19-mortality-and-more-image

Health News Roundup: Eisai files for approval of Alzheimer's drug in Japan; WHO recommends that China monitor excess COVID-19 mortality and more

Source from : devdiscourse - 12 days ago

China said on Saturday that nearly 60,000 people with COVID-19 had died in hospital since it abandoned its zero-COVID policy last month, a big jump from the figures it reported prior to facing ...See details»


Eisai Aims to Advance Gastrointestinal Cancer Treatment with Research Across Multiple Tumor Types at ASCO GI 2023

Source from : Asia One - 11 days ago

TOKYO, Jan 18, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today the presentation of research across various types of gastrointestinal cancers during the 2023 American Society of Clinical ...See details»


Eisai files for approval of Alzheimer's drug in Japan

Source from : health.economictimes.indiatimes - 13 days ago

Japanese drugmaker Eisai Co Ltd said on Monday it had submitted a marketing authorisation application in Japan for its Alzheimer's drug lecanemab, which was recently granted accelerated approval ...See details»


EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER'S DISEASE IN EUROPE

Source from : Yahoo Finance - 18 days ago

TOKYO and CAMBRIDGE, Mass., Jan. 10, 2023 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate ...See details»


Eisai, Biogen's Alzheimer's drug price should not dent demand - analysts

Source from : Yahoo News - 19 days ago

(Reuters) - The $26,500-per-year price tag for Eisai Co Ltd and Biogen Inc's newly approved Alzheimer's disease drug is slightly above expectations, but should not dent demand for the promising ...See details»


Eisai Co Ltd ADR (ESALY)

Source from : Investing - 5 days ago

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...See details»


ESALY Eisai Co., Ltd.

Source from : Seeking Alpha - 9 days ago

**NM signifies a non meaningful value. A dash signifies the data is not available.See details»


EISAI FILES MARKETING AUTHORIZATION APPLICATION FOR ANTI-AMYLOID-BETA PROTOFIBRIL ANTIBODY LECANEMAB FOR EARLY ALZHEIMER'S DISEASE IN JAPAN

Source from : Stockhouse - 13 days ago

TOKYO and CAMBRIDGE, Mass., Jan. 15, 2023 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate ...See details»